Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panel Punts On PET For Initial Diagnosis Of Cancer In Dense-Breasted Women

This article was originally published in The Gray Sheet

Executive Summary

Public input prior to the formulation of questions for a technology assessment potentially could have allowed a more thorough evaluation of PET scanning in the initial diagnosis of cancer in dense-breasted women by the Medicare Coverage Advisory Committee's Diagnostic Imaging Panel June 19

You may also be interested in...

PET Cancer Coverage Decision Saves Dense-Breast Indication For Another Day

The Centers for Medicare & Medicaid Services is inviting interested parties to submit a separate coverage request for FDG-PET in women who have dense breast tissue

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts